Results 151 to 160 of about 104,823 (289)
The impact of systemic long‐term medications for the development of age‐related macular degeneration
Acta Ophthalmologica, EarlyView.Abstract Purpose Age‐related macular degeneration (AMD) is a leading cause of central vision loss in the elderly; however, the systemic factors that modulate its incidence and progression remain unclear. We sought to determine whether long‐term use of systemic medications, including diabetes and antithrombotic medications, corticosteroids and ...
Hanna Heloterä +3 more
wiley +1 more source
Practical management of NSCLC patients with long-term bevacizumab treatment: a report of four cases
, 2013 GJM Herder,1 H Codrington,2 CD Colder,3 JG Aerts4,51St Antonius Hospital, Nieuwegein, The Netherlands; 2Haga Hospital, The Hague, The Netherlands; 3St Jansdal Hospital, Harderwijk, The Netherlands; 4Amphia Hospital, Breda; 5Erasmus MC Rotterdam, The ...
Aerts JG +3 more
core
Acta Ophthalmologica, EarlyView.Abstract Purpose To assess the impact of biosimilar ranibizumab and on‐patent faricimab market entry on pricing and utilization trends and describe national variation in off‐label bevacizumab use in Europe. Methods Interrupted time series analysis of quarterly sales data (Q1 2018–Q2 2024) in 11 European countries evaluated ranibizumab utilization and ...
Elif Car +3 more
wiley +1 more source
Benign Migratory Glossitis in a Patient With Cholangiocarcinoma due to Targeted Drug Therapy. [PDF]
Clin Case RepOral Manifestation of Targeted Therapy: Benign Migratory Glossitis. ABSTRACT During the course of targeted drug therapy, a cancer patient may manifest a myriad of systemic and oral toxicities. This has a direct impact on the patient's QOL. This clinical image highlights a rarely‐encountered oral mucosal alteration called benign migratory glossitis in a
Gurav S, Singh GP, Jain R.
europepmc +2 more sources
Advanced Coats’ disease treated with intravitreal bevacizumab combined with laser vascular ablation
, 2014 Victor M Villegas,1 Aaron S Gold,1 Audina M Berrocal,2 Timothy G Murray11Ocular Oncology and Retina, Miami, FL, USA; 2Department of Ophthalmology, Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami, Miami, FL, USAPurpose: To ...
Berrocal AM +3 more
core
Acta Ophthalmologica, EarlyView.Abstract Coats disease diagnosed in adulthood is a rare idiopathic retinal telangiectatic vasculopathy that may differ in phenotype from childhood‐diagnosed cases. This systematic review synthesizes current evidence to characterize its clinical spectrum, imaging features, treatment outcomes and underlying mechanisms, with a focus on immunovascular ...
Catarina Francisco +2 more
wiley +1 more source
reservedA partire dal 1986, anno dell’immissione in commercio del primo anticorpo monoclonale ad uso terapeutico, si è verificato un notevole incremento nel numero di farmaci appartenenti a questa classe approvati dall’EMA e dall’FDA.
SOTTORIVA, CHIARA
core
Acta Ophthalmologica, EarlyView.Abstract Purpose To evaluate real‐world safety experience with aflibercept 8 mg in a large case series of patients with neovascular age‐related macular degeneration (nAMD). Methods Due to a high proportion of patients on short treatment intervals, patients with nAMD at a Danish tertiary retina clinic were systematically switched to aflibercept 8 mg ...
Mary Graciya Karunainathan +12 more
wiley +1 more source
Takotsubo cardiomyopathy in two men receiving bevacizumab for metastatic cancer
, 2008 Thérèse H Franco, Ahmed Khan, Vishal Joshi, Beje ThomasDepartment of Internal Medicine, University of Connecticut, Farmington, CT, USAAbstract: Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor ...
Ahmed Khan +3 more
core
Five Advances in the Last 50 Years: Liver Malignancies
World Journal of Surgery, EarlyView.
Alex B. Blair, Timothy M. Pawlik
wiley +1 more source